当地时间4月15日，Mural Oncology宣布终止其新型免疫疗法nemvaleukin的所有临床开发计划，并裁员90%。该决定是在对黑色素瘤II期ARTISTRY-6研究和铂耐药卵巢癌III期ARTISTRY-7研究数据进行评估后做出的。尽管这一壮举似乎相当反常，但Mural的股价却强劲上涨，收盘时飙升134%至4152.01万美元。

The finding means that building larger AI models for protein design, and feeding them more data, will produce predictably ...

By Maggie Fick and Bhanvi Satija LONDON (Reuters) -Trump administration cuts across federal health agencies have sent shivers ...

“We were given the opportunity to engage with Genentech in 1977, two years before its IPO [initial public offering], and we ...

The U.S. biotech sector had already been through a brutal few years before the latest market crash. Robert F. Kennedy Jr.’s ...

Elevation Oncology has become the second biotech this week to face calls from an activist investor to wind down the company.

爱美客在4月8日公布了关于收购韩国REGEN Biotech公司的控股权进展，引起了市场的广泛关注。随着企业间的并购活动逐渐增多，消费者也开始关注这些决策将如何影响个人护肤和美容行业的未来。这一消息发出后，不少人纷纷讨论，爱美客此举是否意味着其将进一步拓展在美容科技领域的布局。

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

Colossal Biosciences says it used novel gene-editing technology to alter gray wolf DNA to breed the animals. Dire wolves ...

Investing.com — 市值约1600万美元的临床阶段生物制药公司Edesa Biotech, Inc. (NASDAQ: EDSA )今日宣布其管理团队变动，任命Peter J. Weiler为首席财务官，自2025年5月1日起生效。Weiler将接替同日卸任的Stephen Lemieux，后者将寻求新的职业发展机会。根据 InvestingPro ...

Biotech company Colossal Biosciences said it has brought back the dire wolf, an animal that went extinct 10,000 years ago, ...

Colossal Biosciences said it used ancient DNA from the extinct species to create three dire wolf pups named Romulus, Remus ...